ArticleEBioMedicine2019
Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways.
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The role of CD36 in immune function: bridging innate and adaptive responses.Frontiers in immunology · 2026Pooled it
- Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes.Journal of diabetes investigation · 2026Article
- PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4-Targeted Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Vildagliptin and Omarigliptin Differentially Bind to DPP-4 Homodimers and Modulate Osteoclast-Mediated Bone Resorption.Comprehensive Physiology · 2026Article
- Coordinated regional association of cathepsins and dipeptidyl peptidases with N-truncated Abeta42, Abeta40, and tau in Alzheimer's brain.Acta neuropathologica communications · 2025Article
- Article
- Imaging flow cytometry: from high - resolution morphological imaging to innovation in high - throughput multidimensional biomedical analysis.Frontiers in bioengineering and biotechnology · 2025Review
- Elevated inflammatory index and future risk of stroke in patients with coronary heart disease: a multicenter prospective cohort study.Frontiers in cardiovascular medicine · 2025Article
- Microbial Interactions with Intestinal Lipid Digestion and Absorption: Emerging Targets for Metabolic Disorders.Research (Washington, D.C.) · 2025Review
- New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control.TouchREVIEWS in endocrinology · 2024Review
- Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study.Frontiers in endocrinology · 2024Article
- Free fatty acids and peripheral blood mononuclear cells (PBMC) are correlated with chronic inflammation in obesity.Lipids in health and disease · 2023Article
- Dipeptidyl Peptidase 4/Midline-1 Axis Promotes T Lymphocyte Motility in Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.JCI insight · 2023Article
- DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.Military Medical Research · 2022Review
- The COVID-19-diabetes mellitus molecular tetrahedron.Molecular biology reports · 2022Review
- Adipose tissue macrophages in remote modulation of hepatic glucose production.Frontiers in immunology · 2022Review
- Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management.Frontiers in endocrinology · 2022Review
- Trelagliptin ameliorates oxygen-glucose deprivation/reperfusion (OGD/R)-induced mitochondrial dysfunction and metabolic disturbance of endothelial cells.Human cell · 2021Article
- Macrophages in Atherosclerosis, First or Second Row Players?Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundWe and others have shown that dipeptidyl peptidase-IV (DPP4) expression is increased in obesity/atherosclerosis and is positively correlated with atherosclerotic burden. However, the mechanism by which DPP4 expression is regulated in obesity remains unclear. In this study, we investigated the pathways regulating the expression of DPP4 on macrophages.
methodsFlowsight® Imaging Flow Cytometry was employed for the detection of DPP4 and immunophenotyping. DPP4 enzymatic activity was measured by a DPPIV-Glo™ Protease Assay kit.
findingsHuman monocytes expressed a moderate level of membrane-bound DPP4. Obese patients with body mass index (BMI) ≥ 30 had a higher level of monocyte DPP4 expression, in parallel with higher levels of HOMA-IR, blood glucose, triglycerides, and non-HDL cholesterol, compared to those in the non-obese (BMI < 30) patients. Oxidized low-density lipoprotein (oxLDL), but not native LDL, up-regulated DPP4 expression on macrophages with a preferential increase in CD36
interpretationOur study suggests a key role for oxLDL and downstream CD36/TLR4/TRIF in regulating DPP4 expression. Increased DPP4 in response to oxidized lipids may represent an integrated mechanism linking post-prandial glucose metabolism to lipoprotein abnormality-potentiated atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.